MAIA 2.58 MAIA Biotechnology, Inc.
| Range: | 0.82-5.99 | Vol Avg: | 111675 | Last Div: | 0 | Changes: | 0.07 |
| Beta: | 0.34 | Cap: | 0.06B | Currency: | USD | Exchange: | AMEX |
| Sector: | Healthcare | IPO: | Thu Jul 28 2022 | Empoloyees: | 13 | ||
| CUSIP: | 552641102 | CIK: | 0001878313 | ISIN: | US5526411021 | Country: | US |
| CEO: | Dr. Vlad Vitoc M.B.A., M.D. | Website: | https://www.maiabiotech.com | ||||
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow